

Revere Healthcare™ identifies key clinical, regulatory, corporate, and sector events that can significantly drive the near-term performance and long-term value creation of biopharmaceutical and medical technology companies.

Revere Healthcare™ provides an unmatched view of the healthcare industry by tracking pipeline and relationship information for all U.S.- and Canadian-listed biopharmaceutical and medical technology companies. This datafeed enables users to make better investment decisions and better manage risk exposure by including information on early- to late-stage drugs and devices in development, pending FDA approvals, upcoming events, mechanisms of action, material licensing and partnerships between companies, key sales, and patent expiration dates, as well as many other financial and fundamental data.

Identify key drivers of a company's late-stage pipeline, including indications and PMOA

Amgen, Inc.: Products & Services

Tradename	Indications	Side Effects	Stage
AMN 75 (Pilot Study) [Oral Tablet]	First-Line Non-Small Cell Lung Cancer (NSCLC)		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Diabetes Resolving Anemia For Treatment Of Anemia		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Anemia In Heart Failure Patients		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Neoadjuvant Breast Cancer In Combination With Standard Preoperative Chemotherapy Regimen		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Bone Cancer Metastases In Breast Cancer		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Bone Cancer Metastases In Prostate Cancer		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Treatment-Induced Bone Loss (TIBL)		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Postmenopausal Osteoporosis		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Oral Mucositis Associated With Radiation Therapy And Chemotherapy For Solid Tumors		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Chronic Immune Thrombocytopenia Purpura (ITP)		NDA Filed
AMN 75 (Pilot Study) [Oral Tablet]	Risk Reduction Of Mortality And Cardiovascular Morbidity In Secondary Hypertension (SH) And Chronic Kidney Disease Undergoing Maintenance Dialysis		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	First-Line Treatment Of Metastatic Ovarian Cancer (Ovarian Cancer)		Phase III
AMN 75 (Pilot Study) [Oral Tablet]	Metastatic And Recurrent Head And Neck Cancer		Phase III

Track upcoming and historical FDA events

Gilead Sciences, Inc.: Healthcare Events

Tradename	Indications	Side Effects	Stage
08/11/2008 - PDUFA Date - Confirmed - None (N/A)	Chronic Hepatitis B Virus (HBV)		NDA Filed
01/09/2008 - PDUFA Date - Estimate - None (N/A)	Prophylaxis And Treatment Of Influenza A And Influenza B In Children Ages One And Older In Capsule Formulation	Nausea, Vomiting, Diarrhea, Headache, Fatigue, Cough	Approved
11/09/2007 - FDA General Disease Discussion - Other (OTHER)	Treatment Of HIV Infection In Combination With Other Antiretrovirals	Headache, Diarrhea, Nausea, Rash	Approved
11/07/2007 - FDA General Disease Discussion - Other (OTHER)	Prophylaxis And Treatment Of Influenza A And Influenza B In Children Ages One Through 12 In Liquid Formulation	Nausea, Vomiting, Diarrhea, Headache, Fatigue, Cough	Approved
11/07/2007 - FDA General Disease Discussion - Other (OTHER)	Prophylaxis And Treatment Of Influenza A And Influenza B In Children Ages One And Older In Capsule Formulation	Nausea, Vomiting, Diarrhea, Headache, Fatigue, Cough	Approved
11/16/2007 - NDA/BLA Submission to FDA - Confirmed - None (N/A)	Pulmonary Infection Related To Cystic Fibrosis (CF)		NDA Filed
10/11/2007 - NDA/BLA Submission to FDA - Estimate - None (N/A)	Chronic Hepatitis B Virus (HBV)		NDA Filed
06/18/2007 - PDUFA Date - Confirmed - None (N/A)	Pulmonary Arterial Hypertension (PAH)	Peripheral Edema, Nasal	Approved

THE HEALTHCARE DATAFEED INCLUDES INFORMATION ON THE FOLLOWING:

- Product events including PDUFA dates, NDA/BLA Filings, FDA Advisory Committee meetings, and key patent expiration dates
- Tradename and generic name of approved drugs and drug candidates
- Historical drug sales information
- Name and ticker of the drug/device developer
- Indication(s) seeking FDA approval
- Drug/device's primary mechanism of action (PMOA)
- Historical data on filings, meetings and dates for over three years

Discover material relationships between companies

Genentech, Inc.: Partners

Dir Ticker	Name	Alerts	Subsidiary	Partnership Types	Keywords
REBY	Reata Holdings Ltd. (REBY)			Development, Investor, Out-licensing, Research Collaboration	Hollmann-La Roche, Big Pharm, Mucosa, Herceptin, Sitagliptin, Gilead - Novartis, Pulmonary, Adipose, Metastasis, Anemia, Sitagliptin - Gilead - Novartis, Nuloparin, Tenecte, Omnitarg, Sitagliptin - Novartis
XOMA	XOMA Limited			Equity Investment, Research Collaboration	Tarceva - Sitagliptin - Gilead - Novartis
CEL	Cell Therapeutics Inc.			In-licensing	Oncology, autoimmune - Sitagliptin - Gilead - Novartis
SGEN	Seattle Genetics, Inc.			In-licensing	SGN-42 - Sitagliptin - Gilead - Novartis
NVS	Novartis AG (NVS)			Novartis, Investor, Marketing, Research Collaboration	Dynacirc, Kalar - Sitagliptin - Gilead - Novartis
ABT	Abbott Laboratories			In-licensing, Out-licensing, Research Collaboration	Humira - Sitagliptin - Gilead - Novartis, ABT-202, ABT-499, semar - Sitagliptin - Gilead - Novartis
BBB	Baxter Inc.			In-licensing, Research Collaboration	Humira, Humira - Sitagliptin - Gilead - Novartis
DSF	DSF Pharmaceuticals, Inc.			In-licensing, Research Collaboration	Tarceva - Sitagliptin - Gilead - Novartis
LEAS	Leas Group Ltd.			Manufacturing	tarceva - Sitagliptin - Gilead - Novartis, sitagliptin - Sitagliptin - Gilead - Novartis
WYE	Wyeth			Manufacturing	Herceptin - Sitagliptin - Gilead - Novartis
AMGN	Amgen, Inc.			Immune Corporation	Immune, ENBREL - Sitagliptin - Gilead - Novartis
BAYV	Bayer AG (BAYV)			Out-licensing	Helveta, Kogenate - Sitagliptin - Gilead - Novartis

KEY FACTS

COVERAGE:	U.S.- and Canadian-traded biopharmaceutical and medical technology companies.
UPDATE FREQUENCY:	Daily
SOURCES:	SEC Filings, press releases, websites, earnings transcripts, and statements from FDA and other government regulatory agencies, as well as primary research by Revere analysts.
HISTORY:	Up to 700 historical events over a three year period.
CAPABILITIES:	In conjunction with its patented technology, Revere's team of healthcare industry analysts ensures the relevancy, accuracy, and comprehensiveness of its products.
METHODOLOGY:	Developed over nine years, Revere uses both computer and human intelligence to mine hard-to-find data.
FILE ACCESS:	http: server as CSV files. For best analyses, Revere provides a recommended data schema. Healthcare information is accessed through SQL queries provided in our data documentation.

DATA ELEMENTS

- Event ID
- Event Date
- Event Type
- Committee
- Subcommittee
- Contact Info
- URL for additional information
- Notes
- Agenda
- Center associated with committee
- Sector ID
- Indication ID
- Product ID
- Proven PMOA (Primary Mechanism of Action)
- Status of Event (cancelled or otherwise)
- Previous Date of Event (if applicable)

REVERE HEALTHCARE™ WITH OUR OTHER PRODUCTS

- **REVERE HIERARCHY™:**
Uncover focused lines of business and direct competitors by indication or primary mechanism of action
- **REVERE TRADENAMES™:**
Identify directly competing drugs/ devices that are approved or in late clinical stage of development
- **REVERE HIERARCHY™ & TRADENAMES™:**
Better understand a product's differentiating characteristics and the competitive landscape
- **REVERE RISC™:**
Gain better visibility into industry sub-sectors and the global marketplace

STATISTICS

Revere Healthcare™	
Biopharmaceuticals	
# Companies (focused)	483(374)
# Drugs	7844
Approved	
- OTC	668
- Generic	1732
- Prescription	2115
Phase III/Pending Approval	867
Phase I/Phase II/Phase II-III	3330
Therapeutic Categories/Subcategories	21/92
Medical Devices	
# Companies (focused)	417(259)
# Devices	15424
Approved	
- Class I/Class II	13768
- Class III	1215
Clinical Trials	281
PMA Filed/510K Filed	32/53
Average Events/Month	11
FDA Meetings (future)	300(10)
NDA/BLA Filings (future)	200(5)
PDUFA (future)	200(60)